53
Zydus Life
532321.NS·NSEAhmedabad INFounded 195225,000 employees
Large CappharmaPublicOncologyMetabolicInfectious Disease
Platform: Saroglitazar
Market Cap
$15B
All Drugs
6
Clinical Trials
10
Failed / Terminated
1
FDA Approved
0
Stock Price & Catalysts (532321.NS)
Loading 532321.NS stock data...
Drug Pipeline (6 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Ribotapinarof | 532-1237 | NDA/BLA | 2 | MET | CholangiocarcinomaRett | ||
| Daracilimab | 532-7557 | Phase 2 | 2 | CD38 | Prostate CaNASH | ||
| Elralucimab | 532-7324 | Phase 1 | 1 | PCSK9 | DMDBladder Ca | ||
| 532-4982 | 532-4982 | Phase 3 | 1 | CDK4/6 | SchizophreniaNB | ||
| 532-7053 | 532-7053 | Phase 1 | 2 | FcRn | Ovarian Ca | ||
| Lirazanubrutinib | 532-2445 | Phase 1 | 2 | USP1 | PTSD |
SEC Filings & Financial Documents
SEC filings are not available for NSE-listed companies.
Zydus Life trades on NSE (IN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (9)